Lawrence P. Carter
YOU?
Author Swipe
View article: Phase 1 study of latozinemab in progranulin‐associated frontotemporal dementia
Phase 1 study of latozinemab in progranulin‐associated frontotemporal dementia Open
INTRODUCTION Heterozygous mutations in the GRN gene lead to reduced progranulin (PGRN) levels in plasma and cerebrospinal fluid (CSF) and are causative of frontotemporal dementia (FTD) with > 90% penetrance. Latozinemab is a human monoclon…
View article: Psychomotor Vigilance Performance in Participants with Excessive Daytime Sleepiness in Obstructive Sleep Apnea or Narcolepsy Compared with SAFTE-FAST Model Predictions
Psychomotor Vigilance Performance in Participants with Excessive Daytime Sleepiness in Obstructive Sleep Apnea or Narcolepsy Compared with SAFTE-FAST Model Predictions Open
NCT02806895, EudraCT 2015-003930-28: A Randomized, Double-Blind, Placebo-Controlled, Crossover On-Road Driving Study Assessing the Effect of JZP-110 on Driving Performance in Subjects With Excessive Sleepiness Due to Obstructive Sleep Apne…
View article: Effects of solriamfetol on on‐the‐road driving in participants with narcolepsy: A randomised crossover trial
Effects of solriamfetol on on‐the‐road driving in participants with narcolepsy: A randomised crossover trial Open
Objective To evaluate the impact of solriamfetol, a dopamine and norepinephrine reuptake inhibitor, on on‐the‐road driving performance in participants with narcolepsy. Methods In this randomised, double‐blind, placebo‐controlled, crossover…
View article: Effects of solriamfetol on on‐the‐road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea
Effects of solriamfetol on on‐the‐road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea Open
Objective To evaluate the impact of solriamfetol, a dopamine and norepinephrine reuptake inhibitor, on on‐the‐road driving in participants with excessive daytime sleepiness (EDS) associated with obstructive sleep apnoea (OSA). Methods Elig…
View article: A Randomized, Double‐Blind, Placebo‐ and Positive‐Controlled, 4‐Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants
A Randomized, Double‐Blind, Placebo‐ and Positive‐Controlled, 4‐Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants Open
Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, is approved (United States and European Union; Sunosi) to treat excessive daytime sleepiness associated with narcolepsy (75‐150 mg/day) or obstructive sleep apnea (37.5‐150 mg…
View article: Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial
Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial Open
Rationale: Excessive daytime sleepiness in patients with obstructive sleep apnea is associated with substantial burden of illness.Objectives: To assess treatment effects of solriamfetol, a dopamine/norepinephrine reuptake inhibitor, on dai…
View article: P004 Solriamfetol for excessive daytime sleepiness in obstructive sleep apnoea: a randomised controlled trial
P004 Solriamfetol for excessive daytime sleepiness in obstructive sleep apnoea: a randomised controlled trial Open
Introduction Obstructive sleep apnoea (OSA) is often associated with persistent excessive daytime sleepiness (EDS) despite sleep apnoea therapy. There are currently no approved treatments in the European Union for the treatment of EDS in t…
View article: P003 Randomised, placebo-controlled study of solriamfetol for excessive daytime sleepiness in narcolepsy types 1/2
P003 Randomised, placebo-controlled study of solriamfetol for excessive daytime sleepiness in narcolepsy types 1/2 Open
Introduction Solriamfetol (formerly JZP-110), a dopamine and norepinephrine reuptake inhibitor, has been approved in the United States to improve wakefulness in adults with excessive daytime sleepiness (EDS) associated with narcolepsy (75–…
View article: 0618 Weight Change Associated with Solriamfetol Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy or Obstructive Sleep Apnea
0618 Weight Change Associated with Solriamfetol Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy or Obstructive Sleep Apnea Open
Solriamfetol is a dopamine and norepinephrine reuptake inhibitor with demonstrated efficacy in treating excessive daytime sleepiness in narcolepsy and obstructive sleep apnea (OSA). Decreased appetite was a common adverse event (AE) in cli…
View article: 0570 Dose Titration Of Solriamfetol In Participants With Obstructive Sleep Apnea From A 6-week Randomized-withdrawal Trial
0570 Dose Titration Of Solriamfetol In Participants With Obstructive Sleep Apnea From A 6-week Randomized-withdrawal Trial Open
Solriamfetol significantly reduced participant-reported excessive daytime sleepiness relative to placebo in two randomized, fixed-dose phase 3 trials involving participants with narcolepsy or OSA. Dosing trends from a phase 3, 6-week, plac…
View article: A randomized study of solriamfetol for excessive sleepiness in narcolepsy
A randomized study of solriamfetol for excessive sleepiness in narcolepsy Open
Objective Solriamfetol (JZP‐110) is a selective dopamine and norepinephrine reuptake inhibitor with wake‐promoting effects. This phase 3 study (NCT02348593) evaluated the safety and efficacy of solriamfetol in narcolepsy. Methods Patients …
View article: Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial
Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial Open
Rationale: Primary treatment of obstructive sleep apnea can be accompanied by a persistence of excessive sleepiness despite adherence. Furthermore, effectiveness of sleep apnea treatment is limited by poor adherence. Currently available ph…
View article: Solriamfetol for the Treatment of Excessive Sleepiness in OSA
Solriamfetol for the Treatment of Excessive Sleepiness in OSA Open
ClinicalTrials.gov; No.: NCT02348619; URL: www.clinicaltrials.gov; EudraCT No.: 2014-005515-16.
View article: A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor
A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor Open
Background: This study evaluated the human abuse potential of solriamfetol (formerly JZP-110), a selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects. Methods: Adults with a recent history of recreati…
View article: Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor
Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor Open
Excessive sleepiness (ES) is associated with several sleep disorders, including narcolepsy and obstructive sleep apnea (OSA). A role for monoaminergic systems in treating these conditions is highlighted by the clinical use of US Food and D…
View article: Evaluation of the effect of JZP-110 in patients with narcolepsy assessed using the Maintenance of Wakefulness Test censored to 20 minutes
Evaluation of the effect of JZP-110 in patients with narcolepsy assessed using the Maintenance of Wakefulness Test censored to 20 minutes Open
In patients with narcolepsy, JZP-110 significantly improved the ability to stay awake compared with placebo, with large effect sizes using both the 40-min and 20-min censored MWT data.
View article: Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy
Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy Open
SXB alone and in combination with modafinil improved subjective ratings of excessive sleepiness and an objective measure of the ability to stay awake to similar extents in NC patients and NWOC patients.